Kate Hasal | Authors

Articles

Thyroiditis in Melanoma Patient Treated With Ipilimumab and Pembrolizumab

March 07, 2015

In an analysis of adverse events following treatment of patients with advanced melanoma with ipilimumab and nivolumab, combination therapy was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis.